Can you take Aldesleukin with Clobazam?

cloBAZam has a major potential interaction with Acute Alcohol Intoxication.

The use of benzodiazepines with alcohol is not recommended. Patients with acute alcohol intoxication exhibit depressed vital signs. The central nervous system depressant effects of benzodiazepines may be additive with those of alcohol, and severe respiratory depression and death may occur. Therapy with benzodiazepines should be administered cautiously in patients who might be prone to acute alcohol intake.

Aldesleukin has a major potential interaction with Autoimmune Disorders.

Aldesleukin may exacerbate existing or activate quiescent autoimmune disease. Therapy with aldesleukin should be administered cautiously in patients with autoimmune diseases.

Aldesleukin has a major potential interaction with Bleeding Disorder.

Aldesleukin induces myelosuppression, primarily thrombocytopenia and anemia. Leukopenia has been reported. Therapy with aldesleukin should be administered cautiously in patients with compromised bone marrow reserve. Clinical monitoring of hematopoietic function is recommended. Subsequent treatment with aldesleukin is contraindicated in patients requiring surgery for GI bleeding or in those patients with bowel ischemia/perforation.

Aldesleukin has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

Aldesleukin induces myelosuppression, primarily thrombocytopenia and anemia. Leukopenia has been reported. Therapy with aldesleukin should be administered cautiously in patients with compromised bone marrow reserve. Clinical monitoring of hematopoietic function is recommended. Subsequent treatment with aldesleukin is contraindicated in patients requiring surgery for GI bleeding or in those patients with bowel ischemia/perforation.

Aldesleukin has a major potential interaction with Cardiovascular Conditions and Disorders.

The use of aldesleukin is contraindicated in patients with abnormal cardiac function as indicated by a thallium stress test. Therapy with aldesleukin should be administered with extreme caution in patients with a normal thallium stress test who have a history of cardiac disease. Close clinical monitoring of cardiac function is required. When adverse events occur that require dosage modification, dosages should be withheld rather than reduced . Subsequent treatment with aldesleukin is contraindicated in patients with sustained ventricular tachycardia, rhythm disturbances uncontrolled or unresponsive to management, recurrent chest pain with ECG changes consistent with angina or myocardial infarction, or pericardial tamponade.

Aldesleukin has a moderate potential interaction with Depression.

Mental status changes such as lethargy, somnolence, depression, confusion or agitation were reported in over 70% of patients administered aldesleukin. Therapy with aldesleukin should be administered cautiously to patients with or predisposition to altered mental status. When adverse events occur that require dosage modification, dosages should be withheld rather than reduced. Clinical monitoring of mental status is recommended.

cloBAZam has a moderate potential interaction with Depression.

Benzodiazepines depress the central nervous system and may cause or exacerbate mental depression and cause suicidal behavior and ideation. Episodes of mania and hypomania have also been reported in depressed patients treated with some of these agents. Therapy with benzodiazepines should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

cloBAZam has a major potential interaction with Drug Dependence.

Benzodiazepines have the potential to cause dependence and abuse. Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use and/or excessive dosages. However, abrupt cessation following continual use of as few as 6 weeks at therapeutic levels has occasionally precipitated withdrawal symptoms. Addiction- prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance when treated with benzodiazepines. It may be prudent to refrain from dispensing large quantities of medication to these patients. After prolonged use or if dependency is suspected, withdrawal of benzodiazepine therapy should be undertaken gradually using a dosage- tapering schedule. If withdrawal symptoms occur, temporary reinstitution of benzodiazepines may be necessary.

Aldesleukin has a major potential interaction with Fluid Retention.

Aldesleukin can cause Capillary Leak Syndrome resulting in ascites or pulmonary edema. Administration of IV fluids may be necessary to maintain organ perfusion and blood pressure. Aldesleukin should be administered cautiously in patients with fixed fluid requirements and/or those adversely affected by fluid overload.

Aldesleukin has a major potential interaction with Gastrointestinal Perforation.

Aldesleukin induces myelosuppression, primarily thrombocytopenia and anemia. Leukopenia has been reported. Therapy with aldesleukin should be administered cautiously in patients with compromised bone marrow reserve. Clinical monitoring of hematopoietic function is recommended. Subsequent treatment with aldesleukin is contraindicated in patients requiring surgery for GI bleeding or in those patients with bowel ischemia/perforation.

Aldesleukin has a major potential interaction with Hypotension.

Hypotension, primarily associated with capillary leak syndrome, has been reported in 85% of patients administered aldesleukin. Seventy-one percent of patients with hypotension required pressor management. Therapy with aldesleukin should be administered cautiously in patients predisposed to hypotension.

Aldesleukin has a major potential interaction with Infection.

The use of aldesleukin may be contraindicated in patients with infections, particularly bacterial diseases. Aldesleukin can interfere with neutrophil chemotaxis and increase the risk of disseminated infections, including bacterial endocarditis and sepsis. Therefore, preexisting bacterial infections should be adequately treated prior to initiation of aldesleukin therapy. Close clinical monitoring of hematopoietic function is recommended during therapy. Since there is increasing evidence that neutrophils may also play important roles in viral and other infections, it may be reasonable in some cases to defer aldesleukin treatment in patients with active nonbacterial infections.

Aldesleukin has a major potential interaction with Liver Disease.

Hepatotoxicity such as elevated bilirubin, transaminase and alkaline phosphatase levels have been reported in over 55% of patients administered aldesleukin. Hepatotoxicity is generally reversible, however, hepatic failure resulting in death has been reported. Therapy with aldesleukin should be administered cautiously in patients with compromised hepatic function. When adverse events occur that require dosage modification, dosages should be withheld rather than reduced. Clinical monitoring of hepatic function is recommended.

Aldesleukin has a major potential interaction with Organ Transplant.

The use of aldesleukin is contraindicated in patients with allograft organ transplants. Aldesleukin possesses immunoregulatory properties that may increase the risk of organ rejection, including enhancement of lymphocyte mitogenesis and cytotoxicity and induction of killer cell activity.

Aldesleukin has a moderate potential interaction with Psychosis.

Mental status changes such as lethargy, somnolence, depression, confusion or agitation were reported in over 70% of patients administered aldesleukin. Therapy with aldesleukin should be administered cautiously to patients with or predisposition to altered mental status. When adverse events occur that require dosage modification, dosages should be withheld rather than reduced. Clinical monitoring of mental status is recommended.

cloBAZam has a moderate potential interaction with Psychosis.

Benzodiazepines depress the central nervous system and may cause or exacerbate mental depression and cause suicidal behavior and ideation. Episodes of mania and hypomania have also been reported in depressed patients treated with some of these agents. Therapy with benzodiazepines should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

Aldesleukin has a major potential interaction with Pulmonary Impairment.

The use of aldesleukin should be restricted to patients with adequate ventilatory function (baseline FEV1 > 2 L or >= 75% of the predicted value based on height and age). Extreme caution should be used in treating patients with normal test results but have a history of pulmonary disease. Pulmonary congestion and dyspnea have been reported in over 50% of patients receiving the recommended dosage of aldesleukin. Respiratory adverse effects are often associated with the capillary leak syndrome induced by aldesleukin and may also include pulmonary edema, respiratory failure requiring intubation, tachypnea, pleural effusion, wheezing, apnea, pneumothorax, hemoptysis, respiratory arrest, and pulmonary emboli. During therapy, pulmonary function should be monitored regularly by clinical examination, assessment of vital signs and pulse oximetry, and arterial blood gas determinations as needed. When toxicities occur that require a dosage modification, doses should be withheld rather than reduced. Subsequent treatment with aldesleukin is contraindicated in patients who develop respiratory failure requiring intubation for longer than 72 hours.

Aldesleukin has a major potential interaction with Renal Dysfunction.

Renal toxicity such as oliguria/anuria and elevated BUN and serum creatinine has been reported in > 60% of patients during aldesleukin therapy. Renal toxicity is generally reversible, however, patients with renal impairment are at increased risk for more severe and prolonged renal dysfunction. Therapy with aldesleukin should be administered cautiously in patients with compromised renal function. Clinical monitoring of renal function is recommended. When adverse events occur that require dosage modification, dosages should be withheld rather than reduced. Subsequent treatment with aldesleukin is contraindicated in patients experiencing renal dysfunction that requires greater than seventy-two hours of dialysis.

cloBAZam has a moderate potential interaction with Renal Dysfunction.

Benzodiazepines are excreted by the kidneys and should be used with caution in patients with impaired renal function and end-stage kidney disease.

Aldesleukin has a major potential interaction with Seizures.

Aldesleukin can induce seizures. Therapy with aldesleukin should be administered with extreme caution in patients with or predisposition to seizure disorders. When adverse events occur that require dosage modification, dosages should be withheld rather than reduced . Subsequent treatment with aldesleukin is contraindicated in patients with repetitive or difficult to control seizures.